Spasojevic, I., Alves da Silva, W. T., Huang, Z., Duan, W., Du, L., Chen, C., … Secord, A. A. (2024). Redox-active Mn porphyrin-based clinical candidate, MnTnBuOE-2-PyP5+ (BMX-001) reduces paclitaxel-induced neuropathy, while suppressing ovarian cancer growth. In Free Radical Biology and Medicine (Vol. 224, pp. S54–S55). Elsevier BV. https://doi.org/10.1016/j.freeradbiomed.2024.10.117

Spasojevic, Ivan, Welida Tamires Alves da Silva, Zhiqing Huang, Weina Duan, Li Du, Cathleen Chen, Jie Cao, et al. “Redox-active Mn porphyrin-based clinical candidate, MnTnBuOE-2-PyP5+ (BMX-001) reduces paclitaxel-induced neuropathy, while suppressing ovarian cancer growth.” In Free Radical Biology and Medicine, 224:S54–55. Elsevier BV, 2024. https://doi.org/10.1016/j.freeradbiomed.2024.10.117.

Spasojevic I, Alves da Silva WT, Huang Z, Duan W, Du L, Chen C, et al. Redox-active Mn porphyrin-based clinical candidate, MnTnBuOE-2-PyP5+ (BMX-001) reduces paclitaxel-induced neuropathy, while suppressing ovarian cancer growth. In: Free Radical Biology and Medicine. Elsevier BV; 2024. p. S54–5.

Spasojevic, Ivan, et al. “Redox-active Mn porphyrin-based clinical candidate, MnTnBuOE-2-PyP5+ (BMX-001) reduces paclitaxel-induced neuropathy, while suppressing ovarian cancer growth.” Free Radical Biology and Medicine, vol. 224, Elsevier BV, 2024, pp. S54–55. Crossref, doi:10.1016/j.freeradbiomed.2024.10.117.

Spasojevic I, Alves da Silva WT, Huang Z, Duan W, Du L, Chen C, Cao J, Zhang S, Lee H, Lo G, Feng J, Mendieta B, Tovmasyan A, Sheng H, Batinic-Haberle I, Secord AA. Redox-active Mn porphyrin-based clinical candidate, MnTnBuOE-2-PyP5+ (BMX-001) reduces paclitaxel-induced neuropathy, while suppressing ovarian cancer growth. Free Radical Biology and Medicine. Elsevier BV; 2024. p. S54–S55.